文献速递泌尿生殖与妇科肿瘤放疗

高危前列腺癌中度大分割质子治疗联合盆腔淋巴结照射的五年结局

Five-Year Outcomes of Moderately Hypofractionated Proton Therapy Incorporating Elective Pelvic Nodal Irradiation for High-Risk Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-12-11

一项前瞻性研究评估中度大分割调强质子治疗(IMPT)同步照射前列腺/精囊与盆腔淋巴结(67.5 Gy 与 45 Gy,25 次)联合雄激素剥夺治疗高危或不利中危前列腺癌的疗效。中位随访 62 个月,5 年无复发生存率 90%、无病生存率 89%,晚期 ≥2 级胃肠道和泌尿生殖道不良事件分别为 16% 和 41%,≥3 级分别为 4% 和 0%。作者认为该方案五年结局令人鼓舞,需 III 期研究评估其相较光子放疗的治疗获益。

要点

  • 5 年无复发生存率 90%、无病生存率 89%,无前列腺癌或治疗相关死亡。
  • 5 年晚期 ≥2 级胃肠道不良事件 16%、≥3 级 4%;≥2 级泌尿生殖道 41%、≥3 级 0%。
  • 作者认为该方案五年结局令人鼓舞,需 III 期研究评估相较光子放疗的治疗获益。

核心结论

  • 作者认为该中度大分割 IMPT 方案用于高危或不利中危前列腺癌取得了令人鼓舞的 5 年无复发生存率、无病生存率和晚期不良事件结局。
  • 作者提出需要一项 III 期研究来评估 IMPT 相较光子放疗是否带来治疗获益。

研究设计与样本

  • 前瞻性研究(ClinicalTrials.gov:NCT02874014),计划样本量为 56 例高危或不利中危前列腺癌患者。
  • 前列腺/精囊与盆腔淋巴结同步照射,剂量分别为 67.5 Gy 和 45 Gy,分 25 次每日照射;全部患者接受雄激素剥夺治疗。
  • 主要终点为晚期胃肠道和泌尿生殖道不良事件,次要终点为 5 年无复发生存率(含无 PSA 复发)和无病生存率。

主要发现

  • 中位年龄 75 岁,中位 PSA 10.5 ng/mL,53 例为高危前列腺癌、2 例为不利中危前列腺癌,中位雄激素剥夺治疗时长 18 个月,中位随访 62 个月。
  • 5 年晚期 ≥2 级和 3 级胃肠道不良事件分别为 16% 和 4%,≥2 级和 3 级泌尿生殖道不良事件分别为 41% 和 0%,无 ≥4 级晚期不良事件。
  • 5 年无复发生存率为 90%、无病生存率为 89%;7 例出现前列腺癌复发,均最初通过 PSA 复发检出。
  • 3 例患者死亡,末次随访时 PSA <0.1 ng/mL;无前列腺癌死亡或治疗相关不良事件死亡。

关键数值与推荐

  • 前列腺/精囊照射剂量 67.5 Gy、盆腔淋巴结 45 Gy,分 25 次每日照射,同步进行。
  • 全部患者接受雄激素剥夺治疗,中位时长 18 个月。
  • PSA 和不良事件在 IMPT 后 3、6、12 个月评估,之后每 6 个月至 5 年,此后每年评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the efficacy of moderately hypofractionated intensity modulated proton therapy (IMPT) targeting the prostate/seminal vesicles and pelvic lymph nodes for high-risk (HR) or unfavorable intermediate-risk (UIR) prostate cancer (PCa). MATERIALS AND METHODS: A prospective study (ClinicalTrials.gov: NCT02874014) of moderately hypofractionated IMPT accrued a target sample size of 56 patients with HR or UIR-PCa. The prostate/seminal vesicles and pelvic lymph nodes were treated simultaneously with 67.5 and 45 Gy, respectively, in 25 daily fractions. All received androgen deprivation therapy. Its primary objective was late gastrointestinal (GI) and genitourinary (GU) adverse events (AEs), and secondary objectives were a recurrence-free rate (RFR), including freedom from prostate-specific antigen (PSA) relapse and disease-free survival (DFS) at 5 years. PSA and AEs were evaluated at 3, 6, and 12 months post-IMPT, then every 6 months for 5 years, and then yearly thereafter. The actuarial rates of late GI and GU AEs, RFR, and DFS were estimated with the Kaplan-Meier method. RESULTS: Median age was 75 years. Median PSA was 10.5 ng/mL. Fifty-three patients had HR-PCa; 2 had UIR-PCa. Median androgen deprivation therapy duration was 18 months. Median follow-up was 62 months. Late grade ≥2 and 3 GI AEs at 5 years were 16% and 4%, respectively. Late grade ≥2 and 3 GU AEs at 5 years were 41% and 0%, respectively. None had a grade ≥4 late AE. At 5 years, RFR and DFS were 90% and 89%, respectively. Seven patients had PCa recurrence, all detected by PSA relapse initially. Three patients died with PSA <0.1 ng/mL at last follow-up. None died of PCa or treatment-related AEs. CONCLUSIONS: This regimen of moderately hypofractionated IMPT for HR or UIR-PCa yielded encouraging 5-year RFR, DFS, and late AE outcomes. A phase III study is needed to assess any therapeutic gain of IMPT compared with photon-based radiation therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Choo R, Hillman DW, Mitchell C, et al. Five-Year Outcomes of Moderately Hypofractionated Proton Therapy Incorporating Elective Pelvic Nodal Irradiation for High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 39672515. doi:10.1016/j.ijrobp.2024.11.115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。